Aarti Drugs Limited has released the transcript for its Q1 FY27 earnings conference call, held on August 3, 2026. The call detailed the company’s financial performance, including a 19% year-on-year revenue growth to INR 703.6 crore and a 30% EBITDA growth to INR 96.9 crore. Management discussed operational resilience, manufacturing expansion, and strategies for API and formulation businesses.
Q1 FY27 Earnings Conference Call Transcript Released
Aarti Drugs Limited has officially published the transcript for its Q1 FY27 Earnings Conference Call, which took place on August 3, 2026. The document provides a detailed account of the discussions between the company’s management and investors regarding the financial results and operational performance for the quarter ended June 30, 2026.
Key Financial Highlights for Q1 FY27
During the call, the company reported a consolidated revenue of INR 703.6 crore, marking a 19% increase compared to INR 590.8 crore in Q1 FY26. EBITDA also saw a significant jump of 30% year-on-year, reaching INR 96.9 crore from INR 74.4 crore. The EBITDA margin stood at 13.8%, an expansion of 120 basis points. Profit After Tax (PAT) was reported at INR 50.1 crore.
On a stand-alone basis, revenue grew by 20% year-on-year to INR 627.6 crore. The API business contributed significantly to sales, with the antibiotic therapeutic category leading at 35.0%. The formulations segment reported revenue of INR 81.6 crore, an 8% increase year-on-year.
Operational Performance and Strategic Initiatives
Management highlighted the company’s operational resilience despite a dynamic global landscape, with no production disruptions or material shortages experienced. Investments in manufacturing expansion, particularly at the Sayakha facility, were discussed, with its utilization reaching nearly 65%. This facility is strategic for enhancing backward integration and supply chain reliability.
The brownfield expansion at the Baddi facility is progressing as planned to nearly double oral solid dosage manufacturing capacity. The company also detailed plans for increasing metformin capacity and obtaining USFDA approval for this key product.
Future Outlook and Growth Drivers
Aarti Drugs expressed confidence in future growth, driven by expanding manufacturing capabilities, a focus on regulated markets, and leveraging backward integration. The company is targeting a volume growth of 10% to 15% over the next two years. Efforts to increase sales in regulated markets through USFDA and European approvals are a key focus.
Source: BSE
